For a patient with lupus anticoagulant (LA), activated coagulation time (ACT) was measured with two different types of devices (HEMOCHRON® 801 and HEMOCHRON® Jr).
Case Report:
ACTs during heparinization measured with the HEMOCHRON® 801 were over the range of measurement, while those with the HEMOCHRON® Jr. reflected an almost normal response to heparin.
Discussion:
The phospholipid contained in an activating agent of the HEMOCHRON® Jr was suggested to have counteracted the effect of LA.
Conclusion:
It was indicated that the coagulation status for LA-positive patients might be better assessed by ACT measured with phospholipid in an activating agent, although careful interpretation is required.
LevineJSBranchDWRauchJ. The antiphospholipid syndrome. N Engl J Med2002; 346: 752–763.
2.
GorkiHMalinovskiVStanbridgeRD. The antiphospholipid syndrome and heart valve surgery. Eur J Cardiothorac Surg2008; 33: 168–181.
3.
AylsworthCLStefanFWoitasK. New technology, old standards: disparate activated clotting time measurements by the Hemochron Jr compared with the standard Hemochron. Ann Thorac Surg2004; 77: 973–976.
4.
PanCMJobesDRiperDV. Modified microsample ACT test for heparin monitoring. J Extra Corpor Technol1996; 28: 16–20.
5.
Accriva Diagnostics, Inc. Package Insert for HEMOCHRON® Jr. ACT+. San Diego, CA.
